Amend HB 1584 (senate committee report) in SECTION 1 of the bill, by striking added Section 1369.213(b), Insurance Code (page 2, lines 36 through 40), and substituting the following:
(b) This section applies only to a drug the use of which is:
(1) consistent with best practices for the treatment of stage-four advanced, metastatic cancer or an associated condition;
(2) supported by peer-reviewed, evidence-based literature; and
(3) approved by the United States Food and Drug Administration.